Mechelen, Belgium; 10 July 2021, 11.10 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced new post-hoc analyses from the Phase 3 SELECTION program, supporting the activity and tolerability of filgotinib, a once-daily, oral JAK1 preferential inhibitor, under investigation for the treatment of patients with moderately to severely active ulcerative colitis (UC). These data were presented at the European Crohn's and Colitis Organisation (ECCO) 16th annual congress.